Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 16/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926972 | 0.83 | ESR1 (0.39) | CYP1A2CYP2D6TSHRMAPK1CYP2C19 | |
| SCHEMBL12070517 | 0.81 | USP2 (0.44) | PDCD1CD274CYP1A2CYP2D6TSHR | |
| SCHEMBL14903961 | 0.77 | PDCD1 (0.48) | PDCD1CD274CYP1A2CYP2D6TSHR | |
| SCHEMBL14926987 | 0.77 | USP2 (0.40) | CYP1A2CYP2D6TSHRMAPK1CYP2C19 | |
| SCHEMBL14926982 | 0.74 | CD274 (0.45) | PDCD1CD274 | |
| SCHEMBL14903976 | 0.71 | PDCD1 (0.53) | PDCD1CD274CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL128848 | 0.69 | RAC1 (0.42) | PDCD1CD274ALDH1A1 | |
| SCHEMBL128040 | 0.69 | RAC1 (0.44) | PDCD1CD274ALDH1A1 | |
| SCHEMBL5999845 | 0.68 | MEN1 (0.56) | CYP1A2CYP2D6TSHRMAPK1CYP2C19 | |
| SCHEMBL30389997 | 0.68 | MEN1 (0.56) | CYP1A2CYP2D6TSHRMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | PDCD1 4176/4885CD274 3356/4885CYP1A2 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.